GridAI Technologies Corp.
GridAI Technologies Corp. is a U.S.-based biotechnology company that develops targeted, non-systemic therapies for gastrointestinal diseases, with product candidates including Adrulipase, Niclosamide, Capeserod, and Latiglutenase. In September 2025 it also acquired Grid AI Corp., adding an AI-driven grid-edge software and device platform for utilities, energy retailers, and large commercial and industrial customers to its operations.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNon-systemic therapeutic candidates designed to act locally in the gastrointestinal tract.
Externally sourced drug programs, including Capeserod, that expand the pipeline.
AI-driven energy orchestration tools for utilities and large power users.
Customers
The biotechnology side of the business is not yet commercial, so its end customers are future patients and the physicians, hospitals, and payers that would adopt approved GI therapies. The newly acquired Grid AI business sells to utilities, energy retailers, and large commercial and industrial customers that need software to manage distributed energy resources and optimize power usage. Until products are commercialized, the company is primarily funded by capital markets rather than customer revenue.
Would buy or prescribe approved non-systemic GI treatments such as Adrulipase and Capeserod for localized disease management.
Buy Grid AI software to coordinate distributed energy resources, improve reliability, and manage grid conditions.
Use the platform to optimize load, integrate on-site assets, and support customer energy programs.
Adopt the platform to automate load management and reduce operating costs through better energy coordination.
Strategy
The core strategy remains advancing GI drug candidates while preserving optionality through in-licensing and acquisitions. The Grid AI acquisition adds a second operating track in energy technology, which could diversify the company if integration succeeds, but near-term execution still depends on financing, development progress, and regulatory milestones.
The company has no revenue and needs capital to support development and operations.
Clinical progress is required to create value from the biotechnology business.
The acquisition could create a second growth platform and broaden the company’s business model.
Geography
The company is headquartered in the United States and its reported operations and financing activity are primarily U.S.-based. No country-level revenue disclosure was provided, and the business remains pre-revenue, so geographic exposure is driven more by where development, financing, and any future commercialization occur than by current sales. The Grid AI acquisition may broaden exposure into utility and industrial energy markets, but the filing does not yet provide a regional revenue split.
Risks
The company remains a pre-revenue, development-stage business with substantial going-concern risk and dependence on external financing. It also faces execution risk from clinical development, regulatory approval, and the integration of a newly acquired energy technology platform that is outside its historical biotech focus.
The company has no revenue, recurring losses, and limited cash, so it must raise capital to continue operations.
Exposure: Biotech development and corporate overhead
Pipeline value depends on successful trials and regulatory approvals for Adrulipase and other candidates.
The company is adding a new energy-tech operating component that requires integration, product alignment, and execution.
Exposure: Grid AI / AmpX platform
The company previously received a bid-price deficiency notice, which can pressure liquidity and investor access.
Exposure: Capital markets access
Accounting
Judgemental itemsWith no product sales, expenses and financing items dominate the income statement and cash flow profile.
Impact: Makes quarterly comparisons highly sensitive to development and financing activity
The Grid AI acquisition requires purchase price allocation and fair value estimates for acquired assets and liabilities.
Impact: Can affect goodwill, intangible assets, and future impairment risk
Prior filings show material non-cash equity compensation to advisors and consultants.
Impact: Inflates operating expenses without immediate cash outflow
Financing structures include debt, convertible debt, and Series H preferred stock with conversion features.
Impact: Affects dilution, equity classification, and interest/financing expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthcare AI Acquisition Corp.
Blank Checks
Absci Corp
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
BioXcel Therapeutics, Inc.
BTAIQ · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
AI Technology Group Inc.
Motors & Generators
Last updated: 24/09/2026